Go Pro
→ [URGENT] Mode Mobile terms changing Aug 14 (From Mode Mobile) (Ad)tc pixel Free VRPX Stock Alerts

Virpax Pharmaceuticals (VRPX) Competitors

Virpax Pharmaceuticals logo
Compare

VRPX vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Virpax Pharmaceuticals stock or one of its competitors? MarketBeat compares Virpax Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Virpax Pharmaceuticals include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW).

How does Virpax Pharmaceuticals compare to Ainos?

Ainos (NASDAQ:AIMDW) and Virpax Pharmaceuticals (NASDAQ:VRPX) are related companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, media sentiment, risk, valuation, profitability and analyst recommendations.

Ainos has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Ainos' return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

In the previous week, Ainos' average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Ainos Neutral
Virpax Pharmaceuticals Neutral

Summary

Ainos beats Virpax Pharmaceuticals on 3 of the 5 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, profitability, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

Alvotech's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

Alvotech has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

In the previous week, Alvotech had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for Alvotech and 0 mentions for Virpax Pharmaceuticals. Alvotech's average media sentiment score of 0.67 beat Virpax Pharmaceuticals' score of 0.00 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Positive
Virpax Pharmaceuticals Neutral

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Alvotech beats Virpax Pharmaceuticals on 5 of the 7 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Aravive?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Aravive (NASDAQ:ARAV) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Aravive's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Aravive N/A N/A N/A

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Aravive Neutral

32.2% of Virpax Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 3.7% of Virpax Pharmaceuticals shares are owned by insiders. Comparatively, 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Aravive is trading at a lower price-to-earnings ratio than Virpax Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
AraviveN/AN/AN/A-$0.90N/A

Summary

Aravive beats Virpax Pharmaceuticals on 5 of the 6 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Atlantic Coastal Acquisition Corp. II?

Virpax Pharmaceuticals (NASDAQ:VRPX) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are related companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, risk, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and profitability.

In the previous week, Virpax Pharmaceuticals' average media sentiment score of 0.00 equaled Atlantic Coastal Acquisition Corp. II'saverage media sentiment score.

Company Overall Sentiment
Virpax Pharmaceuticals Neutral
Atlantic Coastal Acquisition Corp. II Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Atlantic Coastal Acquisition Corp. II's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Virpax PharmaceuticalsN/A -1,554.34% -338.29%
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

Summary

Virpax Pharmaceuticals and Atlantic Coastal Acquisition Corp. II tied by winning 2 of the 4 factors compared between the two stocks.

How does Virpax Pharmaceuticals compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, dividends, valuation, media sentiment, earnings, risk, analyst recommendations and profitability.

In the previous week, Biofrontera had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 1 mentions for Biofrontera and 0 mentions for Virpax Pharmaceuticals. Biofrontera's average media sentiment score of 0.00 equaled Virpax Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Biofrontera Neutral
Virpax Pharmaceuticals Neutral

Biofrontera has higher revenue and earnings than Virpax Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
Virpax PharmaceuticalsN/AN/A-$15.19M-$123.25N/A

Biofrontera's return on equity of 0.00% beat Virpax Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
Virpax Pharmaceuticals N/A -1,554.34%-338.29%

32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.7% of Virpax Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Biofrontera beats Virpax Pharmaceuticals on 4 of the 6 factors compared between the two stocks.

Get Virpax Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for VRPX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRPX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VRPX vs. The Competition

Export
MetricVirpax PharmaceuticalsPharmaceuticals IndustryHealthcare SectorNASDAQ Exchange
Market CapN/A$12.77B$7.16B$12.47B
Dividend YieldN/A2.73%2.59%9.45%
P/E Ratio0.00799.05282.2524.66
Price / SalesN/A738.07583.2488.79
Price / CashN/A73.1571.2359.99
Price / BookN/A10.9211.095.90
Net Income-$15.19M$2.82B$3.50B$336.31M

Virpax Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VRPX
Virpax Pharmaceuticals
N/AN/AN/AN/A$0.00N/AN/A7
AIMDW
Ainos
N/A$0.12
-7.4%		N/A-28.8%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.19
flat		N/A-90.6%$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:VRPX) was last updated on 8/2/2026 by MarketBeat.com Staff.
From Our Partners
One signature away. Expected within months.
On May 21, 2026, a federal bank board unanimously approved a nearly $3 billion loan to build a gold mine on Am...
Behind the Markets | Sponsoredtc pixel
Your withdrawal order could cost you in taxes
If you have $2M or more saved, the 4% rule points to roughly $92,000 a year - but it's a single-variable answe...
SmartAsset | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
This AI fund posted a 34 percent annualized payout last month
One small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...
Investors Alley | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...
Porter & Company | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
I’m betting on Peter Thiel’s next winner. Here’s why.
SpaceX's $1.75 trillion IPO turned more than 4400 employees into millionaires, according to The New York Times...
The Oxford Club | Sponsoredtc pixel